Cambridge Cognition Holdings PLC- Cambridge-based neuroscience technology company - Appoints Stephen Symonds as chief financial officer with effect ‘in due course’.

Symonds’s most recent role was as chief financial officer at pre-clinical services provider Envigo, where he spent four years in the role and nine years at the company since 2013.

In addition, Director of Research & Innovation Francesca McCormack has been appointed as chief scientist, while current Chief Scientific Officer Jenny Bartnett steps down at the end of April to focus on Cambridge Cognition spin out Monument Therapeutics.

Current stock price: 176.55 pence, down 3.3% on Wednesday

12-month change: up 79%

Copyright 2022 Alliance News Limited. All Rights Reserved.